This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

High-risk compound

Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-FOR-NOW — current cost / risk / redundancy puts it below the line.

Browse

Muscimol

Extensively Studied

Direct GABA-A agonist from Amanita muscaria — rare mechanism (most "GABAergics" are PAMs), but the actual experience is sedation +…

Aliases (5)

Amanita muscaria active · Fly agaric active · 5-aminomethyl-3-isoxazolol · Agarin · Pantherine

TYPICAL DOSE

50-250 mg

Pre-bed PRN

ROUTE

Oral (capsule)

Oral

CYCLE

N/A — not recommended at all

Continuous / daily

STORAGE

Room temp; cool dry place

Room temp

Overview

What is Muscimol?

Muscimol is the principal psychoactive constituent of Amanita muscaria mushrooms. It is a potent and selective GABA-A receptor agonist used non-medically for sedation and altered consciousness.

Key Benefits

Produces sedation, anxiolysis, and dream-like states, may aid sleep onset and depth at low doses, and is used recreationally and traditionally in some cultures for ritual or relaxation effects.

Mechanism of Action

Acts as a high-affinity full agonist at GABA-A receptors, particularly delta-subunit-containing extrasynaptic receptors, increasing tonic chloride conductance and producing sedation, ataxia, and dissociative or oneiric subjective effects.

Pharmacokinetics

PeakHalf-life

Approximate curve — visual aid only, not data-precise PK

▸Brand options4 known

Amanita muscaria activeFly agaric activeAgarinPantherine

Status"Not federally scheduled in US (Louisiana exempt for research only; FL, MS state-level restrictions). Amanita muscaria itself unscheduled federally. FDA position (Dec 2024): muscimol is an unapproved food additive — products containing it are adulterated."

Research Indications

Most Effective

Benzodiazepines / Z-drugs / barbiturates

positive allosteric modulators (PAMs), enhance GABA's effect but don't open channels alone

Effective

Theanine, taurine, glycine, "GABA supplements"

indirect / mixed / barely cross BBB / weak modulators

Investigational

Phenibut, baclofen

GABA-B agonists, completely different receptor family

Peptide Interactions

Alcohol:

Avoid

Additive CNS depression; multiple deaths in case reports involve co-use

Benzodiazepines, Z-drugs:

Avoid

Synergistic respiratory depression

phenibut:

Avoid

GABA-A direct agonism + GABA-B agonism = compounded sedation, dependence on phenibut side worsens

baclofen:

Avoid

Same — GABA-A + GABA-B layered depression

gaba-supplement:

Avoid

No real interaction (oral GABA barely crosses BBB) but redundant intent

Opioids, barbiturates, ketamine:

Avoid

Compounded CNS depression, respiratory depression

Quality Indicators

✓

Tested third-party COA

Reputable brands publish a Certificate of Analysis for identity, potency, and contaminant testing.

✓

GMP-certified manufacturing

Look for cGMP / NSF / USP certifications on the label.

Proprietary blends

Avoid products that hide individual ingredient amounts inside a "proprietary blend."

✗

No origin or sourcing info

Unbranded or no-COA capsules from anonymous sellers carry quality and adulteration risk.

What to Expect

Week 1
Baseline tolerability. Most chronic-use supplements have no acute signal.
Week 2-4
Subtle baseline shift — sleep quality, mood, recovery markers.
Week 4-8
Reach steady state. Re-assess subjective + objective markers.
Month 3+
Long-term maintenance dose if benefit confirmed; otherwise stop.

Side Effects & Safety

Common (>10% users): Nausea, vomiting, ataxia, drowsiness, motor impairment, time distortion, residual next-day sedation
Less common (1-10%): Vivid hallucinations, delirium, autonomic effects (sweating, salivation, mydriasis, dry mouth), urinary retention, paradoxical agitation
Rare-serious (<1% but worth knowing): Seizures (more common with raw / high ibotenic acid), respiratory depression, coma, cardiovascular collapse, death (FDA NPDS reports cite multiple deaths associated with muscimol/Amanita products 2023-2025)
Specific watch periods:
- Diamond Shruumz outbreak (mid-2024): 180 illnesses, 73 hospitalizations, 3 potentially associated deaths in 34 states. Subsequent testing showed muscimol present alongside undeclared substances.
- FDA warning letters Dec 2024 + Sept 2025 (Blue Forest Farms 09/11/2025) explicitly reference delirium, seizures, coma, respiratory depression, and death as adverse events.

Quality risk dwarfs pharmacological risk. Even if you trust pure muscimol pharmacology, you cannot trust gas-station gummies. CDC's MMWR (Charlottesville 2023-2024 cluster) found Schedule I substances mixed into nootropic gummies sold as Amanita products.